Anthony Petrone

“And the follow-up would be just on Gemini study expected to be completed by the end of Just wondering on timing for when we could actually see the Gemini data next year, would it be at ADA of 2027?”

“I hope everyone's doing well, and congrats here on the progress on the IDE study. Maybe Paul and or Bob just, you know, one on just mapping integration. In the last, at HRS, we talked about M-Pulse Magnet being compatible with Abbott's N-Sight.”

“I think, Mike, we talked about, you know, the additional doses at the upper end of the range for Afreza, pediatric Afreza, and maybe when will those be available, and once all of the cartridges are available, what do you think the mix will be in terms of dosing and then you know how does that translate into gross…”

“Maybe I'm going back to the just traditional IG market, Bivigam, you know, some of the PPTA data out there still kind of showing, you know, kind of an erratic pattern with distributor stocking.”

“Great analyst meeting, and thanks for the presentation from Dr. Day as well as the guidance. Maybe to start with the percentage of low-volume, high-risk prostate cases that Dr. Day highlighted, how many of those can actually transition into focal one therapies when you think of leveraging MRI biopsy?”